Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Neuritin 1 unlocks new pathway to treat obesity without reducing food intake

Is it possible to treat obesity without reducing food intake? A new study co-led by Dr. Antonio Zorzano and Dr. Manuela Sánchez-Feutrie at the Institute for Research in Biomedicine (IRB Barcelona) suggests that this might be a possibility, at least in animal m

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Is it possible to treat obesity without reducing food intake? A new study co-led by Dr. Antonio Zorzano and Dr. Manuela Sánchez-Feutrie at the Institute for Research in Biomedicine (IRB Barcelona) suggests that this might be a possibility, at least in animal models. Published in Nature Communications, the research identifies a key role for Neuritin 1, a protein previously linked to the nervous system, which is also produced in brown adipose tissue, where it acts as a powerful driver of energy expenditure and metabolic health.

Unlike current anti-obesity and antidiabetic drugs, such as Ozempic or tirzepatide, which work by suppressing appetite, Neuritin 1 boosts energy burning without affecting food intake.

By increasing the levels of Neuritin 1 specifically in brown fat, we observed that the animals burned more energy, which helped prevent fat accumulation." Dr. Antonio Zorzano, professor at the University of Barcelona and researcher at CIBERDEM

This metabolic boost led to significant improvements in several health indicators, including reduced weight gain, improved insulin sensitivity, and lower liver inflammation, even in animals fed high-calorie diets.

Neuritin 1: a new player in energy metabolism

Previously described for its role in neuronal plasticity, Neuritin 1 is now shown to have a metabolic function in brown fat, a type of fat specialised in generating heat through a process known as thermogenesis. This process involves burning energy to maintain body temperature, particularly in response to cold. In this context, Neuritin 1 stimulates mitochondrial activity and promotes the expression of thermogenic genes.

To trigger its expression, the researchers used a viral vector that drives Neuritin 1 overexpression exclusively in thermogenic fat cells. The result was a sustained increase in metabolic activity, without affecting food consumption or physical activity in the animals.

"These findings point to Neuritin 1 as a promising therapeutic candidate for treating obesity and its associated conditions, such as type 2 diabetes and fatty liver disease, through a mechanism that differs from current approaches," highlights Dr. Sánchez-Feutrie.

Relevance to human health

Beyond the animal model results, genetic data in humans also show a correlation between Neuritin 1 and susceptibility to obesity, reinforcing the potential relevance of the discovery. The team is currently exploring ways to translate these findings into a future therapeutic strategy.

The study was made possible thanks to the contributions of several IRB Barcelona core facilities, including Bioinformatics and Biostatistics, Functional Genomics, Protein Expression, and Histopathology. It also involved collaborators from international institutions such as the CNRS (France), Karolinska Institutet (Sweden), and the University of Houston (USA).

Sánchez-Feutrie, M., et al. (2025). Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue. Nature Communications. doi.org/10.1038/s41467-025-62255-2

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01In safety assessment, the consequences of being wrong are significant. How do you think about uncertainty and model limitations for safety and discovery?

Uncertainty and model limitations are critical in safety assessment. There is clearly greater potential for animal or human harm from an incorrect safety assessment than from making the wrong molecule in early discovery, although uncertainty matters in both contexts. It is important to distinguish different types of uncertainty. Aleatoric uncertainty reflects irreducible randomness in a task, while epistemic uncertainty is model-related, such as hallucinations or lack of knowledge. For LLM systems, we use multiple methods to measure consistency and we have built fact-checking approaches in which a separate LLM independently verifies the primary engine's outputs. For QSAR models, including our SAR work around seizure liability, we can use statistical metrics such as confidence intervals to quantify and communicate uncertainty. Understanding that uncertainty exists and communicating it in both safety and discovery is critical. Uncertainty metrics tell us where potential blind spots may exist in our modelling allowing us to take action to improve over time. This applies to both safety and discovery. The aim is not to pretend AI removes uncertainty, but to make uncertainty visible so scientists can make better-informed decisions. Download the Full PDF to Revisit James McDonagh's Insights on AI in Drug Safety Discovery

Source: www.news-medical.net ↗
02What do you think the future holds for deep learning with regards to drug discovery?

I think we're only just scratching the surface at the moment. I think over the next couple of years, we'll start to see some major strides. Obviously, showing the effects on target identification takes some time with new molecules but, certainly, the repositioning effects should be seen in a few years. I think there is great promise in terms of being able to really tap into a much broader chemical space, so we can have a much wider and more varied chemical palette to be able to pick the best molecules for drug discovery from. Also, accelerating the ways in which we can look at the data and glean much more information from it can help us both in terms of patient selection for clinical trials and in terms of being able to pick up signals of efficacy and safety much earlier.

Source: www.news-medical.net ↗
03What is carb cycling?

Carb cycling is an attempt to fine-tune your carbohydrate consumption to alter many aspects of your metabolism. Your plan will include the same protein intake each day but vary carbohydrates according to your activity. Your carb cycling plan may have three low or zero carb days, two moderate carb days, and two high carb days. Meeting your calorie requirements will require including more fats on low-carb days. Carb cycling needs much more planning than a usual calorie-controlled diet. One way is to match your carb cycling to your physical activity. If you go to the gym thrice a week, you could have carbs on those days. The carbs provide energy for your workout, prevent fatigue, and avoid the muscle loss sometimes seen with dieting. The days when you eat little to no carbs force your body to generate energy from other sources, like proteins and fats. But the days when you eat more carbohydrates might reverse this change. You must only eat a high-carb diet on the days you have a heavy workout, which uses up the calories.

Source: www.medicinenet.com ↗
04What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
05What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →